Lexicon Pharmaceuticals, Inc. (LXRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 15.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.54% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
- Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
- LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities
- Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
- Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
- Lexicon (LXRX) Q2 2026 Earnings Call Transcript
- Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings
- Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Lexicon Pharmaceuticals, Inc..
Full LXRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.